IP Verse

Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione - EP2797581

The patent EP2797581 was granted to Amgen Europe on May 6, 2020. The application was originally filed on Dec 26, 2012 under application number EP12808662A. The patent is currently recorded with a legal status of "Revoked".

EP2797581

AMGEN EUROPE
Application Number
EP12808662A
Filing Date
Dec 26, 2012
Status
Revoked
Aug 27, 2021
Grant Date
May 6, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GALENICUM HEALTH SLUFeb 8, 2021GALENICUM HEALTH SLUADMISSIBLE
KRKAFeb 5, 2021HOEFER & PARTNER PATENTANWALTE MBBADMISSIBLE
GENERICS UKJan 19, 2021ELKINGTON AND FIFEADMISSIBLE

Patent Citations (47) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2002054899
DESCRIPTIONUS2004029832
DESCRIPTIONUS2004087546
DESCRIPTIONUS2004091455
DESCRIPTIONUS2004190609
DESCRIPTIONUS2004220144
DESCRIPTIONUS2005100529
DESCRIPTIONUS2005143344
DESCRIPTIONUS2005143420
DESCRIPTIONUS2005203142
DESCRIPTIONUS2005214328
DESCRIPTIONUS2005222209
DESCRIPTIONUS2005239842
DESCRIPTIONUS2006030594
DESCRIPTIONUS2006122228
DESCRIPTIONUS2006154880
DESCRIPTIONUS2006188475
DESCRIPTIONUS2007048327
DESCRIPTIONUS5632984
DESCRIPTIONUS5635517
DESCRIPTIONUS5770589
DESCRIPTIONUS5800819
DESCRIPTIONUS6001368
DESCRIPTIONUS6015803
DESCRIPTIONUS6218369
DESCRIPTIONUS6225348
DESCRIPTIONUS6281230
DESCRIPTIONUS6962940
DESCRIPTIONWO2004103274
DESCRIPTIONWO2010093588
DESCRIPTIONWO9803502
DESCRIPTIONWO9854170
INTERNATIONAL-SEARCH-REPORTUS2007155791
INTERNATIONAL-SEARCH-REPORTUS6962940
INTERNATIONAL-SEARCH-REPORTWO0104195
INTERNATIONAL-SEARCH-REPORTWO2012083017
OPPOSITIONEP2962690
OPPOSITIONUS2007155791
OPPOSITIONUS2008234359
OPPOSITIONUS6448323
OPPOSITIONUS6962940
OPPOSITIONWO0025777
OPPOSITIONWO0104195
OPPOSITIONWO2006111980
OPPOSITIONWO2011060290
OPPOSITIONWO2012083017
OPPOSITIONWO2013101810

Non-Patent Literature (NPL) Citations (21) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- JENS T. CARSTENSEN, Drug Stability: Principles & Practice, 2d. Ed., MARCEL DEKKER, (1995), pages 379 - 80-
EXAMINATION- Sonali S. Bharate ET AL, "Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review", Journal of Excipients and Food Chemicals, (20101230), pages 3 - 26, URL: http://ojs.abo.fi/index.php/jefc/article/view/26, XP055131570-
OPPOSITION- Anonymous, "Amine", Wikipedia, the free encyclopedia, (20210129), Wikipedia, the free encyclopedia, URL: https://en.wikipedia.org/wiki/Amine, (20221117), XP055982526-
OPPOSITION- ARTHUR H. KIBBE, "Lactose", ARTHUR H. KIBBE, KIBBE A.H. (ED.)., Handbook of Pharmaceutical Excipients, WASHINGTON, DC; US , American Pharmaceutical Assoc. [u.a.] , (20000101), pages 276 - 285, 024282, ISBN 978-0-85369-381-9, XP002473793-
OPPOSITION- Augsburger Larry L., Stephen W. Hoag, "DC Binders and fillers", Pharmaceutical Dosage Forms: Tablets, CRC Press, (20080101), vol. 2, pages 182 - 193, XP055982528-
OPPOSITION- AULTON, M.E., "28 Coating of tablets and multiparticulates", Pharmaceutics: The Science of Dosage Form Design, (20020000), pages 441 - 448, XP055281347-
OPPOSITION- Aulton M. E., "Coating of tablets and multiparticulates", Pharmaceutics: The Science of Dosage Form Design. 2nd ed., Churchill Livingstone , (20020101), pages 441 - 446, ISBN 978-0-387-08755-9, XP055281347-
OPPOSITION- "CHAPTER 46", REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, (20000000), XP055779249-
OPPOSITION- "CHMP Assessment Report", European Medicines Agency, (20090000), XP055779300-
OPPOSITION- Cunningham Charles, Ngoc Do, Thomas P. Farrell, "Stability of Six Model Drug Products Coated with PVA-Based Opadry® II", Colorcon, (20100101), Colorcon, (20221117), XP055982539-
OPPOSITION- CUNNINGHAM et al., "Stability Evaluation of Two Non-Synthetic Pigments for Use in Fully Formulated Film Coating Systems", Colorcon, (20100000), page 1, XP055780375-
OPPOSITION- Cunningham, Et Al., "Stability Evaluation of Two Non-Synthetic Pigments for Use in Fully Formulated Film Coating Systems", Colorcon, (20100101), pages 1 - 1, Colorcon, (20210301), XP055780375-
OPPOSITION- Fujii T., Makoto Noami, Kelzo Tomita, Yoshihiro Furuya, "PVA copolymer: the new coating agent", Pharmaceutical Technology Europe, (20081001), vol. 20, page 32,34,36,38,39, XP055982532-
OPPOSITION- Lieberman Herbert A., Leon Lachman, Joseph B. Schwart, "Diluents", Pharmaceutical Dosage Forms: Tablets. 2nd ed., Marcel Dekker, (19890101), vol. 1, pages 93 - 96, XP055982537-
OPPOSITION- Nancy Walsh, "Otezla Disappoints in RA - Efficacy of apremilast in rheumatoid arthritis no different from placebo", MEDPAGE TODAY, (20150325), MEDPAGE TODAY, URL: https://www.medpagetoday.com/rheumatology/arthritis/50659, (20180411), XP055466491-
OPPOSITION- ROWE et al., "Handbook of Pharmaceutical Excipients", Handbook of Pharmaceutical Excipients sixth edition, (20090000), pages 136 - 138, 206-208, 364-369, 404-407, 564-565, 581-582, XP055780371-
OPPOSITION- Rowe, Et Al., "Handbook of Pharmaceutical Excipients sixth edition", Handbook of Pharmaceutical Excipients sixth edition, (20090101), pages 136 - 138, 206-208, 364-369, 404-407, 564-565, 581-582, XP055780371-
OPPOSITION- Sahoo C. K., S. R. M. Rao, M, Sudhakar, "HPMC a biomedical polymer in pharmaceutical dosage forms", Journal of Chemical and Pharmaceutical Sciences, (20151001), vol. 8, no. 4, pages 875 - 881, XP055982516-
OPPOSITION- "TABLE 11.1 Moisture and Oxygen Permeability of Pure Polymeric Films (Film Thickness = ~100 Microns)", Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms (Handbook, (20170000), XP055779282-
OPPOSITION- Genovese Mark C., Jarosova Katerina, Cieślak Dorota, Alper Jeffrey, Kivitz Alan, Hough Douglas R., Maes Peter, Pineda Lilia, Chen Mindy, Zaidi Farrukh, "Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study : APREMILAST IN PATIENTS WITH ACTIVE RA", Arthritis & Rheumatology, John Wiley & Sons, Inc., US, US , (20150701), vol. 67, no. 7, doi:10.1002/art.39120, ISSN 2326-5191, pages 1703 - 1710, XP055982438
OPPOSITION- Shah, K.R. ; Hussain, M.A. ; Hubert, M. ; Farag Badawy, S.I., "Form conversion of anhydrous lactose during wet granulation and its effect on compactibility", International Journal of Pharmaceutics, ELSEVIER, NL, NL , (20080605), vol. 357, no. 1-2, doi:10.1016/j.ijpharm.2008.02.008, ISSN 0378-5173, pages 228 - 234, XP022637101

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents